Piebaldism with café‐au‐lait macules resulting from a novel mutation of KIT gene in a three‐generation Chinese family
Skin Research and Technology · 2023
DOI: 10.1111/srt.13352 ↗Kurz gefasst
Fallbericht in der Zeitschrift Skin Research and Technology, 2023. Verfasst von Xiaorong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Piebaldism, Pigmentation Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The 14th five-year Key Project of Military Logistics Scientific Research in 2021: Study on detection and application of radiation-damaged cell microenvironment….
Abstract (Originalsprache)
Background
Piebaldism is a rare, autosomal dominant, and congenital pigmentary disorder characterized by stable depigmentation of the skin and white forelock. Mutations in KIT or SLUG genes result in piebaldism. Most individuals with piebaldism have a family history of the disorder.
Methods
In this paper, we report a case of piebaldism with café‐au‐lait macules resulting from a novel mutation of KIT gene c.1982C > T (p.Thr661Ile) in a three‐generation Chinese family. The whole‐exome sequencing, mitochondrial gene 3000X, and bioinformatics tools were used to identify the mutation in this new‐found pedigree. In addition, we searched the databases of “Punmed, Chinese National Knowledge Infrastructure, CMJD, WANFANG MED ONLINE”, reviewed 88 cases of piebaldism caused by KIT gene mutation, and summarized the relationship between clinical phenotype and genotype of piebaldism through logistic regression and other statistical methods.
Results
The proband and her affected mother carried a heterozygous c.1982C > T missense mutation (p.Thr661Ile) on KIT gene. Bioinformatics analysis hinted that it had potential pathogenicity. The data showed that piebaldism patients with cafè‐au‐lait macules had KIT mutations almost located in the intracellular tyrosine kinase domain and were mostly related to the severe clinical phenotype of piebaldism.
Conclusion
The new heterozygous c.1982C > T missense mutation on KIT caused piebaldism with café‐au‐lait macules in this Chinese family. This study provides a new reference index for clinicians to judge the severity of clinical phenotypes of piebaldism, broadens the understanding of the correlation between clinical phenotypes and genotypes of piebaldism, and provides reference of genetic counseling and prenatal diagnosis for affected families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Department of Dermatology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
- Department of Dermatology, Affiliated Hospital of North China University of Science and Technology, Tangshan, China.
Förderung
- The 14th five-year Key Project of Military Logistics Scientific Research in 2021: Study on detection and application of radiation-damaged cell microenvironment…
Zitieren
APA
Li, X., Xing, X., Liang, X., Song, C., Yang, J., Ren, D., & Zhou, Y. (2023). Piebaldism with café‐au‐lait macules resulting from a novel mutation of KIT gene in a three‐generation Chinese family. Skin Research and Technology. https://doi.org/10.1111/srt.13352
Vancouver
Li X, Xing X, Liang X, Song C, Yang J, Ren D, et al. Piebaldism with café‐au‐lait macules resulting from a novel mutation of KIT gene in a three‐generation Chinese family. Skin Research and Technology. 2023. doi:10.1111/srt.13352
BibTeX
@article{Li2023,
author = {Li, Xiaorong and Xing, Xiaojing and Liang, Xiaoqiang and Song, Cuihao and Yang, Jie and Ren, Dan and Zhou, Yong},
title = {Piebaldism with café‐au‐lait macules resulting from a novel mutation of KIT gene in a three‐generation Chinese family},
journal = {Skin Research and Technology},
year = {2023},
doi = {10.1111/srt.13352}
}
EUVIMED